KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Total Liabilities (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Total Liabilities for 16 consecutive years, with $51.4 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Total Liabilities fell 0.62% year-over-year to $51.4 billion, compared with a TTM value of $51.4 billion through Sep 2024, down 0.62%, and an annual FY2023 reading of $52.0 billion, down 2.11% over the prior year.
  • Total Liabilities was $51.4 billion for Q3 2024 at Thermo Fisher Scientific, up from $51.1 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $54.3 billion in Q4 2021 and bottomed at $30.1 billion in Q1 2020.
  • Average Total Liabilities over 5 years is $44.2 billion, with a median of $50.3 billion recorded in 2023.
  • The sharpest move saw Total Liabilities fell 2.9% in 2021, then surged 67.61% in 2022.
  • Year by year, Total Liabilities stood at $34.5 billion in 2020, then soared by 57.14% to $54.3 billion in 2021, then decreased by 2.11% to $53.1 billion in 2022, then fell by 2.11% to $52.0 billion in 2023, then fell by 1.17% to $51.4 billion in 2024.
  • Business Quant data shows Total Liabilities for TMO at $51.4 billion in Q3 2024, $51.1 billion in Q2 2024, and $51.6 billion in Q1 2024.